Einzeltreffer — DigiBib

Icariin (ICA), a prenylated flavanol glycoside present in abundant quantities in Epimedium sagittatum , has shown promise in the treatment and prevention of Alzheimer's disease. Damage to synaptic plasticity induced by amyloid-beta-mediated neurotoxicity is considered a main pathological mechanism driving the learning and memory deficits present in patients with Alzheimer's disease. This study investigated the neuroprotective effects of icariin in an A β 1-42 -induced rat model of Alzheimer's disease. Our results showed that A β 1-42 injection induced loss of learning and memory behaviour in the Morris water maze, which could be reversed with intragastric administration of ICA. Furthermore, ICA reversed decreases in PSD-95, BDNF, pTrkB, pAkt, and pCREB expressions and prevented deterioration of synaptic interface structure. These findings indicate that ICA may improve synaptic plasticity through the BDNF/TrkB/Akt pathway and provide further evidence for its clinical application to improve learning and memory in patients with Alzheimer's disease.

Titel:	Icariin Attenuates Synaptic and Cognitive Deficits in an A β <subscript>1-42</subscript> -Induced Rat Model of Alzheimer's Disease.
Autor/in / Beteiligte Person:	Sheng, C ; Xu, P ; Zhou, K ; Deng, D ; Zhang, C ; Wang, Z
Link:	Zum Volltext
Zeitschrift:	BioMed research international, Jg. 2017 (2017), S. 7464872
Veröffentlichung:	New York, NY : Hindawi Pub. Co., 2017
Medientyp:	academicJournal
ISSN:	2314-6141 (electronic)
DOI:	10.1155/2017/7464872
Schlagwort:	Alzheimer Disease chemically induced Alzheimer Disease pathology Amyloid beta-Protein Precursor toxicity Animals Cognitive Dysfunction pathology Hippocampus drug effects Hippocampus pathology Humans Maze Learning drug effects Memory drug effects Memory Disorders pathology Neuronal Plasticity drug effects Neuroprotective Agents Peptide Fragments toxicity Rats Alzheimer Disease drug therapy Cognitive Dysfunction drug therapy Flavonoids administration & dosage Memory Disorders drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Biomed Res Int] 2017; Vol. 2017, pp. 7464872. <i>Date of Electronic Publication: </i>2017 Sep 19. MeSH Terms: Alzheimer Disease / drug therapy ; Cognitive Dysfunction / drug therapy ; Flavonoids / administration & dosage ; Memory Disorders / drug therapy ; Alzheimer Disease / chemically induced ; Alzheimer Disease / pathology ; Amyloid beta-Protein Precursor / toxicity ; Animals ; Cognitive Dysfunction / pathology ; Hippocampus / drug effects ; Hippocampus / pathology ; Humans ; Maze Learning / drug effects ; Memory / drug effects ; Memory Disorders / pathology ; Neuronal Plasticity / drug effects ; Neuroprotective Agents ; Peptide Fragments / toxicity ; Rats References: Eur J Pharmacol. 2010 Jan 25;626(2-3):213-8. (PMID: 19782061) ; Oncotarget. 2017 Jun 27;8(26):42648-42663. (PMID: 28487495) ; PLoS One. 2016 Mar 14;11(3):e0151397. (PMID: 26974541) ; PLoS One. 2014 Aug 07;9(8):e104616. (PMID: 25101849) ; J Neurosci. 2014 Nov 5;34(45):14995-5008. (PMID: 25378165) ; Neurobiol Aging. 2017 Apr;52:196-213. (PMID: 28317649) ; J Neurosci. 2017 Jan 4;37(1):152-163. (PMID: 28053038) ; Evid Based Complement Alternat Med. 2015;2015:235265. (PMID: 25705234) ; J Biol Chem. 2011 May 27;286(21):18414-25. (PMID: 21460223) ; Neurosci Lett. 2017 Feb 3;639:36-42. (PMID: 28034780) ; Neuroreport. 2004 Apr 29;15(6):955-9. (PMID: 15076714) ; PLoS One. 2013 May 21;8(5):e64460. (PMID: 23700479) ; J Neuropathol Exp Neurol. 2013 May;72(5):386-95. (PMID: 23584198) ; Behav Brain Res. 2017 Mar 30;322(Pt A):145-156. (PMID: 28093254) ; Mol Neurodegener. 2017 Mar 21;12 (1):27. (PMID: 28327181) ; Mol Neurobiol. 2015 Dec;52(3):1477-1493. (PMID: 25354497) ; Int J Biol Sci. 2014 Jan 21;10 (2):181-91. (PMID: 24550686) ; Front Mol Neurosci. 2017 Feb 08;10 :32. (PMID: 28228716) ; J Neurosci. 2015 Apr 29;35(17):6893-902. (PMID: 25926464) ; Mol Psychiatry. 2013 Apr;18(4):451-60. (PMID: 23399915) ; Behav Brain Res. 2016 Nov 1;314:106-15. (PMID: 27498145) ; Pharmacol Biochem Behav. 2015 Nov;138:40-8. (PMID: 26364923) ; Nat Rev Neurol. 2017 May;13(5):260. (PMID: 28338075) ; J Pharm Biomed Anal. 2016 May 10;123:63-73. (PMID: 26874256) ; J Neurosci. 2016 Nov 9;36(45):11532-11543. (PMID: 27911757) ; PLoS One. 2014 May 23;9(5):e96485. (PMID: 24858841) ; Nature. 2016 Oct 6;538(7623):99-103. (PMID: 27680698) ; J Alzheimers Dis. 2014;42(4):1347-55. (PMID: 25024337) ; Learn Mem. 2012 Nov 15;19(12):561-70. (PMID: 23154927) ; J Appl Physiol (1985). 2014 Oct 15;117(8):910-20. (PMID: 25170066) ; Neural Regen Res. 2016 Sep;11(9):1480-1486. (PMID: 27857754) ; Mol Neurobiol. 2017 Sep;54(7):4833-4846. (PMID: 27501805) ; Neurobiol Learn Mem. 2013 Jul;103:34-8. (PMID: 23578839) ; Alzheimers Res Ther. 2017 Feb 17;9(1):10. (PMID: 28212683) ; Biol Pharm Bull. 2015;38(10):1439-49. (PMID: 26424009) ; Can J Physiol Pharmacol. 2012 Nov;90(11):1446-55. (PMID: 23181273) ; Int J Mol Sci. 2016 Jan 27;17 (2):null. (PMID: 26828481) ; BMC Complement Altern Med. 2016 Aug 26;16(1):320. (PMID: 27565551) ; Int J Neuropsychopharmacol. 2014 Jun;17 (6):871-81. (PMID: 24513083) ; Cereb Cortex. 2015 Sep;25(9):3107-21. (PMID: 24860020) ; Neurobiol Dis. 2008 May;30(2):234-42. (PMID: 18356065) ; J Neurosci. 2015 Dec 9;35(49):16018-33. (PMID: 26658856) ; Biochemistry. 2003 Nov 11;42(44):12749-60. (PMID: 14596589) ; Dement Geriatr Cogn Dis Extra. 2016 Dec 9;6(3):559-567. (PMID: 28101102) ; Pharmacol Biochem Behav. 2010 Sep;96(3):301-5. (PMID: 20566405) ; Biomed Res Int. 2015 ;2015 :302653. (PMID: 26649298) ; J Mol Neurosci. 2015 Nov;57(3):325-34. (PMID: 26266487) ; Biochim Biophys Acta. 2015 Aug;1852(8):1665-75. (PMID: 25960150) ; PLoS One. 2011;6(6):e21660. (PMID: 21738757) ; Trends Neurosci. 2016 Sep;39(9):597-604. (PMID: 27445124) ; Neuropharmacology. 2014 Jan;76 Pt C:639-56. (PMID: 23602987) Substance Nomenclature: 0 (Amyloid beta-Protein Precursor) ; 0 (Flavonoids) ; 0 (Neuroprotective Agents) ; 0 (Peptide Fragments) ; VNM47R2QSQ (icariin) Entry Date(s): Date Created: 20171024 Date Completed: 20180607 Latest Revision: 20181113 Update Code: 20231215 PubMed Central ID: PMC5625750

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Icariin Attenuates Synaptic and Cognitive Deficits in an A β <subscript>1-42</subscript> -Induced Rat Model of Alzheimer's Disease.